PubMed Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al
Biosimilar risk is about molecule + label + indication Biosimilar launch risk is governed by: Residual patents that cover molecule and/or clinical use Exclusivity periods tied to reference product approvals Jurisdiction-specific rules on interchangeability and substitution Small-molecule generic risk is about Orange Book patent mapping Generic entry risk is driven by: Whether Paragraph IV certifications can be made on a legally defensible non-infringement or invalidity position Whether stays and settlements delay launch Strategic implication: Lillys risk is bifurcated: insulin and select biologics face biosimilar ramp risk, while GLP-1 and other small molecules face Orange Book and method-of-use mapping risk
A study of 600,000 VA patients found GLP-1 users had lower addiction risks
Clinical evidence shows that Ozempic promotes dose-dependent weight loss when combined with lifestyle changes
Resources on peptide storage and quality provide valuable insights for maintaining compound integrity
In people with gastroparesis, the stomachs motility or its ability to contract and move food through the digestive tract is significantly reduced or completely absent
